Schizophrenia International Research Institute (SIRS)

March 29–April 2 2025, Chicago, United States

SIRS

Neuro Psych

Chicago

Poster

Open-Label, Randomized Study to Assess Safety and Efficacy of Slow and Accelerated Switching to Xanomeline/Trospium From Standard of Care Atypical Antipsychotics in Participants With Schizophrenia

David Walling, Naomi Marbot, Lara Shirikjian, Edwin Gomez, Lauren White, Kimball Johnson, Pierre Nicolas, Andrew Thorpe, Gerard Zitnik, Scott Vuocolo, Ken Kramer.

foot note heading
U.S. Medical Information & Services

Access medical information and resources for U.S. healthcare professionals.

Medical Information Online  External new tab
Medical Information Contact Center

800-321-1335 (toll free U.S. only)

Mon - Fri, 8am - 5pm ET

Report Adverse Events or Product Quality Complaints

800-721-5072 (toll free U.S. only)

For outside the U.S., visit our global site to report Adverse Events, Product Quality Complaints or submit a Medical Information inquiry.

Follow us

      

Legal notice  External new tab

Privacy notice center  External new tab

Your Privacy Choices

Trademarks  External new tab

© 2025 Bristol-Myers Squibb Company
BMS Medical is a trademark of Bristol-Myers Squibb Company
NO-US-2500378 12/25